Moving Beyond Population‐Level Analyses to Characterize Individual Heterogeneity in CMAP Responses Would Enhance the Assessment of Its Clinical Utility
Open Access
- 16 January 2026
- journal article
- Published by Wiley in European Journal of Neurology
- Vol. 33 (1) , e70503
Abstract
No abstract availableThis publication has 3 references indexed in Scilit:
- Compound Muscle Action Potential (CMAP) Amplitude Trajectories and Pattern in Adults with 5q‐Spinal Muscular Atrophy Receiving Nusinersen Therapy: A Multicenter, Binational Observational StudyEuropean Journal of Neurology, 2025
- Nusinersen in adults with 5q spinal muscular atrophy: a non-interventional, multicentre, observational cohort studyThe Lancet Neurology, 2020
- Nusinersen versus Sham Control in Infantile-Onset Spinal Muscular AtrophyNew England Journal of Medicine, 2017